Hansoh Pharmaceutical Group Company Limited (HK:3692) has released an update.
Hansoh Pharmaceutical’s subsidiary, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., has achieved a milestone with its fourth New Drug Application for Ameile (Aumolertinib Mesilate Tablets) being accepted by China’s National Medical Products Administration. Ameile, a pioneering third-generation EGFR-TKI drug developed in China, has been approved for various treatments of non-small cell lung cancer and included in the National Reimbursement Drug List after successful negotiations.
For further insights into HK:3692 stock, check out TipRanks’ Stock Analysis page.
